We demonstrate that VASH2 is overexpressed in human pancreatic cancer and functions as a gemcitabine-resistance factor by Jun proto-oncogene (JUN) dependent transactivation of ribonucleotide reductase regulatory subunit M2 (RRM2). The gene discussed is VASH2; the disease is pancreatic neoplasm.